She concluded that these new data “allow us to carefully select patients who can benefit from celecoxib. It should definitely be used with caution, but patients with a high risk for colon cancer and a low risk for cardiovascular disease are going to receive a significant benefit.”
“Studies such as Dr. Bertagnolli's are reinvigorating this avenue of research, with major implications for public health,” said Dr. Scott M. Lippman, professor of clinical cancer prevention at the University of Texas M.D. Anderson Cancer Center, Houston.